Neurobiological factors linking personality traits and major depression

Canadian Journal of Psychiatry

Volumn 53, Issue 1, 2008, Pages 6-13

  Foster, Jane A ^a,b   MacQueen, Glenda ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Brain derived neurotrophic factor; Depression; Genetics; Personality; Serotonin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN; SEROTONIN;

BIOLOGICAL TRAIT; BRAIN REGION; CINGULATE GYRUS; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NEUROANATOMY; NEUROBIOLOGY; NEUROSECRETORY CELL; NEUROSIS; PERSONALITY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNAL TRANSDUCTION;

EID: 39049114486     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370805300103     Document Type: Review

References (134)

1. Gray JR, Thompson PM. Neurobiology of intelligence: science and ethics. Nat Rev Neurosci. 2004;5:471-482.
2. Mendez MF. What frontotemporal dementia reveals about the neurobiological basis of morality. Med Hypotheses. 2006;67:411-418.
3. Stein DJ. The neurobiology of evil: psychiatric perspectives on perpetrators. Ethn Health. 2000;5:303-315.
4. Raz A, Fan J, Posner MI. Neuroimaging and genetic associations of attentional and hypnotic processes. J Physiol Paris. 2006;99:483-491.
5. Rahman Q. The neurodevelopment of human sexual orientation. Neurosci Biobehav Rev. 2005;29:1057-1066.
6. Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry. 2006;11:336-351.
7. Zimmer C. The neurobiology of the self. Sci Am. 2005;293:92-96, 98, 100-101.
8. Kessler RC. The effects of stressful life events on depression. Annu Rev Psychol. 1997;48:191-214.
9. De Marco RR. The epidemiology of major depression: implications of occurrence, recurrence, and stress in a Canadian community sample. Can J Psychiatry. 2000;45:67-74.
10. de Beurs E, Beekman A, Geerlings S, et al. On becoming depressed or anxious in late life: similar vulnerability factors but different effects of stressful life events. Br J Psychiatry. 2001;179:426-431.
11. Nemeroff CC. Early-life adversity, CRF. Dysregulation, and vulnerability to mood and anxiety disorders. Psychopharmacol Bull. 2004;38:14-20.
12. Cummings S, Elde R, Ells J, et al. Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study. J Neurosci. 1983;3:1355-1368.
13. Swanson LW, Sawchenko PE, Rivier J, et al. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983;36:165-186.
14. Antoni FA. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev. 1986;7:351-378.
15. Berkenbosch F, van Oers J, del Rey A, et al. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science. 1987;238:524-526.
16. Sapolsky R, Rivier C, Yamamoto G, et al. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science. 1987;238:522-524.
17. Whitnall MH. Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. Prog Neurobiol. 1993;40:573-629.
18. Sternberg EM, Glowa JR, Smith MA, et al. Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats. Brain Res. 1992;570:54-60.
19. Makino S, Smith MA, Gold PW. Increased expression of corticotropin- releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology. 1995;136:3299-3309.
20. Anisman H, Lu ZW, Song C, et al. Influence of psychogenic and neurogenic stressors on endocrine and immune activity: differential effects in fast and slow seizing rat strains. Brain Behav Immun. 1997;11:63-74.
21. Bowers G, Cullinan WE, Herman JP. Region-specific regulation of glutamic acid decarboxylase (GAD) mRNA expression in central stress circuits. J Neurosci. 1998;18:5938-5947.
22. Wong YN, Cassano WJ Jr, D'Mello AP. Acute-stress-induced facilitation of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology. 2000;71:354-365.
23. Bauer ME, Perks P, Lightman SL, et al. Restraint stress is associated with changes in glucocorticoid immunoregulation. Physiol Behav. 2001;73:525-532.
24. Butterweck V, Winterhoff H, Herkenham M. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry. 2001;6:547-564.
25. Marti O, Garcia A, Velles A, et al. Evidence that a single exposure to aversive stimuli triggers long-lasting effects in the hypothalamus-pituitary- adrenal axis that consolidate with time. Eur J Neurosci. 2001;13:129-136.
26. Tan Z, Nagata S. PVN c-fos expression, HPA axis response and immune cell distribution during restraint stress. J Uoeh. 2002;24:131-149.
27. Reyes TM, Walker JR, DeCino C, et al. Categorically distinct acute stressors elicit dissimilar transcriptional profiles in the paraventricular nucleus of the hypothalamus. J Neurosci. 2003;23:5607-5616.
28. Simpkiss JL, Devine DP. Responses of the HPA axis after chronic variable stress: effects of novel and familiar stressors. Neuro Endocrinol Lett. 2003;24:97-103.
29. MacNeil G, Sela Y, McIntosh J, et al. Anxiogenic behavior in the light-dark paradigm following intraventricular administration of cholecystokinin-8S, restraint stress, or uncontrollable footshock in the CD-1 mouse. Pharmacol Biochem Behav. 1997;58:737-746.
30. Harris RB, Gu H, Mitchell TD, et al. Increased glucocorticoid response to a novel stress in rats that have been restrained. Physiol Behav. 2004;81:557-568.
31. Van den Hove DL, Blanco CE, Aendekerk B, et al. Prenatal restraint stress and long-term affective consequences. Dev Neurosci. 2005;27:313-320.
32. Chotiwat C, Harris RB. Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress. Horm Behav. 2006;50:489-495.
33. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci. 2004;29:185-193.
34. Yehuda R. Stress and glucocorticoid. Science. 1997;275:1662-1663.
35. Cervantes P, Gelber S, Kin FN, et al. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci. 2001;26:411-416.
36. Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res. 1999;33:363-370.
37. Holsboer F, Lauer CJ, Schreiber W, et al. Altered hypothalamic-pituitary- adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology. 1995;62:340-347.
38. Heuser IJ, Schweiger U, Gotthardt U, et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry. 1996;153:93-99.
39. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol. 2003;23:155-168.
40. Kunzel HE, Binder EB, Nickel T, et al. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology. 2003;28:2169-2178.
41. Bschor T, Adli M, Baethge C, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology. 2002;27:470-478.
42. McCleery JM, Goodwin GM. High and low neuroticism predict different cortisol responses to the combined dexamethasone - CRH test. Biol Psychiatry. 2001;49:410-415.
43. Zobel A, Barkow K, Schulze-Rauschenbach S, et al. High neuroticism and depressive temperament are associated with dysfunctional regulation of the hypothalamic-pituitary-adrenocortical system in healthy volunteers. Acta Psychiatr Scand. 2004;109:392-399.
44. Bos EH, Bouhuys AL, Geerts E, et al. Cognitive, physiological, and personality correlates of recurrence of depression. J Affect Disord. 2005;87:221-229.
45. LeBlanc J, Ducharme MB. Influence of personality traits on plasma levels of cortisol and cholesterol. Physiol Behav. 2005;84:677-680.
46. Portella MJ, Harmer CJ, Flint J, et al. Enhanced early morning salivary cortisol in neuroticism. Am J Psychiatry. 2005;162:807-809.
47. Mangold DL, Wand GS. Cortisol and adrenocorticotropic hormone responses to naloxone in subjects with high and low neuroticism. Biol Psychiatry. 2006;60:850-855.
48. Oswald LM, Zandi P, Nestadt G, et al. Relationship between cortisol responses to stress and personality. Neuropsychopharmacology. 2006;31:1583-1591.
49. Tyrka AR, Mello AF, Mello MF, et al. Temperament and hypothalamic- pituitary-adrenal axis function in healthy adults. Psychoneuroendocrinology. 2006;31:1036-1045.
50. McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci. 2001;933:265-277.
51. Duman RS, Vaidya VA. Molecular and cellular actions of chronic electroconvulsive seizures. J Ect. 1998;14:181-193.
52. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett. 2002;321:65-68.
53. Pham K, Nacher J, Hof PR, et al. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci. 2003;17:879-886.
54. Xu H, Luo C, Richardson JS, et al. Recovery of hippocampal cell proliferation and BDNF levels, both of which are reduced by repeated restraint stress, is accelerated by chronic venlafaxine. Pharmacogenomics J. 2004;4:322-331.
55. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005;1063:32-39.
56. Rosenbrock H, Koros E, Bloching A, et al. Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. Brain Res. 2005;1040:55-63.
57. Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol Behav Neurol. 1998;11:111-119.
58. Adler CM, Holland SK, Schmithorst V, et al. Changes in neuronal activation in patients with bipolar disorder during performance of a working memory task. Bipolar Disord. 2004;6:540-549.
59. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29:417-426.
60. Thompson JM, Gallagher P, Hughes JH, et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry. 2005;186:32-40.
61. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034-5043.
62. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
63. Chumakov VN, Livanova LM, Krylin VV, et al. Effects of chronic neuroticization on the monoaminergic systems of different structures in the brains of rats with different typological characteristics. Neurosci Behav Physiol. 2006;36:605-611.
64. Swinkels WA, van Emde Boas W, Kuyk J, et al. Interictal depression, anxiety, personality traits, and psychological dissociation in patients with temporal lobe epilepsy (TLE) and extra-TLE. Epilepsia. 2006;47:2092-2103.
65. Caetano SC, Kaur S, Brambilla P, et al. Smaller cingulate volumes in unipolar depressed patients. Biol Psychiatry. 2006;59:702-706.
66. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain. 1995;118(Pt 1):279-306.
67. Larsson M, Pedersen NL, Stattin H. Associations between iris characteristics and personality in adulthood. Biol Psychol. 2007.
68. Yucel M, Harrison BJ, Wood SJ, et al. State, trait and biochemical influences on human anterior cingulate function. Neuroimage. 2007;34:1766-1773.
69. Smith MA, Makino S, Kvetnansky R, et al. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15:1768-1777.
70. Ueyama T, Kawai Y, Nemoto K, et al. Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. Neurosci Res. 1997;28:103-110.
71. Vollmayr B, Faust H, Lewicka S, et al. Brain-derived-neurotrophic-factor (BDNF) stress response in rats bred for learned helplessness. Mol Psychiatry. 2001;6:471-474, 358.
72. Ashe PC, Chlan-Fourney J, Juorio AV, et al. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res. 2002;956:126-135.
73. Roceri M, Hendriks W, Racagni G, et al. Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Mol Psychiatry. 2002;7:609-616.
74. Roceri M, Cirulli F, Pessina C, et al. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry. 2004;55:708-714.
75. Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology. 2002;27:133-142.
76. Vaidya VA, Marek GJ, Aghajanian GK, et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17:2785-2795.
77. Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry. 2003;54:703-709.
78. Altar CA, Laeng P, Jurata LW, et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci. 2004;24:2667-2677.
79. Li B, Suemaru K, Cui R, et al. Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci. 2007.
80. Linden AM, Vaisanen J, Lakso M, et al. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci. 2000;14:27-37.
81. Chen AC, Shin KH, Duman RS, et al. ECS-induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J Ect. 2001;17:27-32.
82. Levkovitz Y, Grisaru N, Segal M. Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. Neuropsychopharmacology. 2001;24:608-616.
83. Adlard PA, Cotman CW. Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. Neuroscience. 2004;124:985-992.
84. Garza AA, Ha TG, Garcia C, et al. Exercise, antidepressant treatment, and BDNF mRNA expression in the aging brain. Pharmacol Biochem Behav. 2004;77:209-220.
85. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
86. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-148.
87. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
88. Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005;57:1068-1072.
89. Aydemir C, Yalcin ES, Aksaray S, et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1256-1260.
90. Pan W, Banks WA, Fasold MB, et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553-1561.
91. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261-264.
92. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology. 2004;29:795-798.
93. Floderus-Myrhed B, Pedersen N, Rasmuson I. Assessment of heritability for personality, based on short-form of Eysenck Personality Inventory: a study of 12 898 twin pairs. Behav Genet. 1982;10:153-162.
94. Kendler KS, Neale MC, Kessler RC, et al. The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch Gen Psychiatry. 1993;50:863-870.
95. Weissman MM, Kidd KK, Prusoff BA. Variability in rates of affective disorders in relatives of depressed and normal probands. Arch Gen Psychiatry. 1982;39:1397-1403.
96. Weissman MM, Wickramaratne P, Merikangas KR, et al. Onset of major depression in early adulthood. Increased familial loading and specificity. Arch Gen Psychiatry. 1984;41:1136-1143.
97. Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60:84-92.
98. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
99. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry. 1998;44:151-162.
100. Reif A, Lesch KP. Toward a molecular architecture of personality. Behav Brain Res. 2003;139:1-20.
101. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999;21:91S-98S.
102. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160:1830-1835.
103. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
104. Heinz A, Goldman D. Genotype effects on neurodegeneration and neuroadaptation in monoaminergic neurotransmitter systems. Neurochem Int. 2000;37:425-432.
105. Schinka JA, Busch RM, Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry. 2004;9:197-202.
106. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet. 2004;127:85-89.
107. Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet. 2004;14:121-129.
108. Nobile M, Cataldo MG, Giorda R, et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry. 2004;56:292-295.
109. Arias B, Catalan R, Gasto C, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23:563-567.
110. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61:1163-1169.
111. Rybakowski JK, Suwalska A, Czerski PM, et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep. 2005;57:124-127.
112. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400-403.
113. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
114. Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8:828-834.
115. Munafo MR, Clark TG, Moore LR, et al. Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry. 2003;8:471-484.
116. Munafo MR, Clark T, Flint J. Does measurement instrument moderate the association between the serotonin transporter gene and anxiety-related personality traits? A meta-analysis. Mol Psychiatry. 2005;10:415-419.
117. Schinka JA. Measurement scale does moderate the association between the serotonin transporter gene and trait anxiety: comments on Munafo et al. Mol Psychiatry. 2005;10:892-893; author reply 895-897.
118. Gonda X, Rihmer Z, Juhasz G, et al. High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. 2007;149:261-266.
119. Munafo MR, Clark TG, Roberts KH, et al. Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. Neuropsychobiology. 2006;53:1-8.
120. Takano A, Arakawa R, Hayashi M, et al. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry. Epub: 2007 Mar 2.
121. Sen S, Nesse RM, Stoltenberg SF, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology. 2003;28:397-401.
122. Itoh K, Hashimoto K, Kumakiri C, et al. Association between brain-derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects. Am J Med Genet B Neuropsychiatr Genet. 2004;124:61-63.
123. Lang UE, Hellweg R, Kalus P, et al. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl). 2005;180:95-99.
124. Willis-Owen SA, Fullerton J, Surtees PG, et al. The Va166Met coding variant of the brain-derived neurotrophic factor (BDNF) gene does not contribute toward variation in the personality trait neuroticism. Biol Psychiatry. 2005;58:738-742.
125. Tochigi M, Otowa T, Suga M, et al. No evidence for an association between the BDNF Va166Met polymorphism and schizophrenia or personality traits. Schizophr Res. 2006;87:45-47.
126. Kobayashi K, Shimizu E, Hashimoto K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:658-663.
127. Yoshida K, Sugawara Y, Higuchi H. Dramatic remission of treatment-resistant depression after the cessation of tricyclic antidepressants. Pharmacopsychiatry. 2006;39:114.
128. Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Va166Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140-143.
129. Bagby RM, Quilty LC, McBride CC. Personality and the prediction of response in major depressive disorder: a randomized control trial comparing interpersonal therapy and pharmacotherapy. Paper presented at the Annual International Conference on Interpersonal Psychotherapy, Toronto (ON): 2006 Nov.
130. Paris J. Neurobiological dimensional models of personality: a review of the models of Cloninger, Depue, and Siever. J Personal Disord. 2005;19:156-170.
131. Gabbard GO. Mind, brain, and personality disorders. Am J Psychiatry. 2005;162:648-655.
132. Miresco MJ, Kirmayer LJ. The persistence of mind-brain dualism in psychiatric reasoning about clinical scenarios. Am J Psychiatry. 2006;163:913-918.
133. Ebstein RP. The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry. 2006;11:427-445.
134. Holzman PS. The fences of psychiatry. Am J Psychiatry. 1985;142:217-218.